F. Stephen Hodi, MD; Sandra Lee, ScD; David F. McDermott, MD; et al.
This phase 2 randomized clinical trial comparing treatment with sargramostim plus ipilimumab, compared to ipilimumab alone in patients with unresectable stage III or IV malanoma, reports longer overall survival and lower toxicity, but no difference in progression-free survival.